Business Context and Reporting Period
This Form 8-K Current Report from DexCom, Inc. covers events occurring on March 6, 2025, with the report filed on March 10, 2025. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director appointments and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size to eleven members.
- New Appointment: Renée Galá was appointed as a director effective March 6, 2025. She is classified as an independent director.
- Term: Ms. Galá's term expires at the 2025 Annual Meeting of stockholders.
Compensation and Governance Details
Upon appointment, Ms. Galá received the following equity compensation under the non-employee director program:
- Initial Grant: Restricted Stock Units (RSUs) with a fair value of $500,000, vesting annually over three years.
- Annual Grant Eligibility: Eligible for a pro-rated annual equity grant with a fair value of $56,986 (based on a base award of $325,000), vesting on the earlier of the first annual stockholder meeting or one year from the grant date.
- Change in Control: Vesting of outstanding equity awards accelerates in full upon a change in control of DexCom.
No material transactions or conflicts of interest were disclosed between Ms. Galá and the company.
Investor Verification Checklist
- Verify the independence status of Renée Galá against Nasdaq listing standards.
- Review the impact of the new director on Board committee assignments (not detailed in this filing).
- Confirm the pro-rata calculation for the annual equity grant ($56,986) relative to the full year base ($325,000).
- Check for any subsequent filings regarding the 2025 Annual Meeting agenda.